Johnson & JohnsonJNJ
Makes prescription medicines, including cancer and immunology drugs, and medical devices for surgery, orthopaedics and heart care.
By financial year
| Figure | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Income | |||||
| Revenue | $78.7bn | $80.0bn | $85.2bn | $88.8bn | $94.2bn |
| Gross profit | $55.3bn | $55.4bn | $58.6bn | $61.4bn | $63.9bn |
| Net income | $20.9bn | $17.9bn | $35.2bn | $14.1bn | $26.8bn |
| Earnings per share (diluted) | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Cash flow | |||||
| Cash from operations | $23.4bn | $21.2bn | $22.8bn | $24.3bn | $24.5bn |
| Capital spending | $3.7bn | $4.0bn | $4.5bn | $4.4bn | $4.8bn |
| Free cash flow | $19.8bn | $17.2bn | $18.2bn | $19.8bn | $19.7bn |
| Share buybacks | $3.5bn | $6.0bn | $5.1bn | $2.4bn | $6.0bn |
| Balance sheet (at the end of the period) | |||||
| Cash and investments | $31.6bn | $22.3bn | $22.9bn | $24.5bn | $20.1bn |
| Total debt | $35.9bn | $41.2bn | $30.8bn | $38.4bn | $49.9bn |
| Net debt (debt less cash) | $4.3bn | $18.9bn | $7.9bn | $13.9bn | $29.8bn |
| Shareholders’ equity | $74.0bn | $76.8bn | $68.8bn | $71.5bn | $81.5bn |
| Shares (diluted average) | 2.67bn | 2.66bn | 2.56bn | 2.43bn | 2.43bn |
By quarter
| Figure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | $22.5bn | $21.9bn | $23.7bn | $24.0bn | $24.6bn | $24.1bn | $25.3bn | $25.4bn |
| Gross profit | $15.4bn | $14.5bn | $16.1bn | $16.7bn | $16.6bn | $16.0bn | $17.3bn | $17.3bn |
| Net income | $3.4bn | $11.0bn | $5.5bn | $5.2bn | $5.1bn | $5.2bn | $5.5bn | $210m |
| Earnings per share (diluted) | — | $4.54 | $2.29 | $2.12 | — | $2.14 | $2.27 | $0.09 |
| Cash flow | ||||||||
| Cash from operations | $7.0bn | $4.2bn | $3.9bn | $9.2bn | $7.3bn | $2.5bn | $8.6bn | $7.7bn |
| Capital spending | $1.6bn | $795m | $1.0bn | $1.2bn | $1.8bn | $1.0bn | $1.3bn | $1.4bn |
| Free cash flow | $5.4bn | $3.4bn | $2.8bn | $8.0bn | $5.5bn | $1.5bn | $7.3bn | $6.4bn |
| Share buybacks | $282m | $2.1bn | $0 | $1.9bn | $1.9bn | $4.0bn | $221m | $1.7bn |
| Balance sheet (at the end of the period) | ||||||||
| Cash and investments | $24.5bn | $38.8bn | $18.9bn | $18.6bn | $20.1bn | $22.1bn | $20.8bn | $17.2bn |
| Total debt | $38.4bn | $52.3bn | $50.8bn | $45.8bn | $49.9bn | $55.0bn | $49.0bn | $44.7bn |
| Net debt (debt less cash) | $13.9bn | $13.5bn | $31.9bn | $27.2bn | $29.8bn | $32.9bn | $28.3bn | $27.4bn |
| Shareholders’ equity | $71.5bn | $78.1bn | $78.5bn | $79.3bn | $81.5bn | $81.2bn | $85.0bn | $81.5bn |
| Shares (diluted average) | — | 2.42bn | 2.42bn | 2.43bn | — | 2.45bn | 2.44bn | 2.45bn |
Charts and live prices are delayed, from TradingView. Market values use each company’s last trade on IEX at the previous close, times the shares in issue from its filings; company figures come from SEC filings. This is information, not investment advice. Where our market data comes from
Company logos are trademarks of their owners, shown only to identify them; the files are from Wikimedia Commons.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.